Identification of Disparities in Personalized Cancer Care—A Joint Approach of the German WERA ConsortiumFlorian Lüke, Alexander Kerscher, Wolfgang Dietmaier et al.|Cancers|2022Cited by 26
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of GermanyMarkus Krebs, Florian Lüke, Florian Haller et al.|European Journal of Cancer|2024Cited by 4
Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patientsAlexander Scheiter, Kirsten Utpatel, Simon Mellin et al.|BMC Medicine|2026Cited by 2
Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patientsNataša Stojanović Gužvić, Christian Werno, Florian Lüke et al.|Molecular Oncology|2024Cited by 1
Additional file 1 of Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patientsAlexander Scheiter, Kirsten Utpatel, Simon Mellin et al.|Open MIND|2026Cited by 0